In primary chronic immune thrombocytopenia, long-term response to splenectomy, with 60% of patients enjoying a treatment-free life, is higher when compared with rituximab and similar to that with continuous thrombopoietin-receptor agonists (TPO-RA) administration. Splenectomy should continue to be offered to patients failing initial treatments in the absence of increased surgery-related risks. The higher lifelong safety concerns with splenectomy (increased risk of infection, shared in part with rituximab, and of thrombosis, in common with TPO-RA) and a mortality <1-2%, justify postponing surgery to the chronic phase, when spontaneous remissions are rarer. Patients failing initial treatment with corticosteroids/intravenous immunoglobulin may use TPO-RA (or rituximab in selected cases) as a bridge to surgery if they prefer to reconsider splenectomy later on, in case of no response, adverse effects or if sustained response after stopping TPO-RA is not attained. Special considerations apply in children aged ≤5 years, with splenectomy playing a marginal role. The recent approval of TPO-RA in children may represent a major advancement.
in patients' blogs could also contribute, given that patients failing splenectomy might be more active and influential.
The annual incidence of ITP ranges from 1Á9 to 6Á4/ 100 000 children and from 1Á6 to 3Á9/100 000 adults (Terrell et al, 2010) , but only 30-50% will require treatment. Based on the experience of major centres ) and on an investigation in hospitalised patients (Moulis et al, 2014a) , up to 20% of ITP cases may be secondary forms. Assuming a 5% splenectomy rate in adults with primary ITP and a negligible rate in children (who represent 20-25% of population in Western countries), we could expect no more than 1-2 splenectomies per year in 1 million.
The aim of this review is to re-evaluate the current place of splenectomy by looking at relevant historical and more recent series published after the International Consensus Report (ICR) and the evidence-based practice guidelines by the American Society of Hematology (ASH) (Neunert et al, 2011) , taking into account the more mature data on the new treatments.
The analysis will suffer some unavoidable limitations due to the lack of direct comparisons. Indeed, in the different series the sequence of treatments and the populations' composition vary in terms of previous treatments, comorbidities, age and gender distribution. Furthermore, data were collected during follow-up periods ranging from a few years to decades, spanning well before the availability of the new treatments. Moreover, patients benefiting from the new treatments might have been previously exposed to several other lines of therapy. Thus, only fragmented comparative analyses are possible.
Pathophysiology of autoimmunity and mechanisms of thrombocytopenia; the role of the spleen production by damaged megakaryocytes which undergo preapoptotic changes, bind to main surface antigens, such as glycoprotein (GP) IIb/IIIa and GPIb-IX-V present on platelets and megakaryocytes. Opsonised platelets, recognised by phagocytes bearing Fcc-receptors, undergo antibody-mediated phagocytosis, primarily in the spleen and liver. Recent studies have also claimed a role for enhanced platelets removal by the liver Ashwell-Morrell receptor, which recognises platelets with defective surface expression of sialic acid. This mechanism may play a role in patients with anti-GP Ib-IX autoantibodies (Grozovsky et al, 2015; Jansen et al, 2015) . A second mechanism entails the destruction of platelets and megakaryocytes by autoreactive cytotoxic T cells (CD8 + ) (Olsson et al, 2003) .
Finally, circulating TPO levels, instead of being increased similar to thrombocytopenias resulting from megakaryocyte hypoplasia, are barely normal or only slightly increased, not exploiting their maximum thrombopoietic potential. In addition, increased concentrations of pro-inflammatory cytokines produced by autoreactive T helper (Th) CD4 + lymphocytes are consistently found. Due to the pro-inflammatory milieu, T and B regulatory lymphocytes (T-regs, CD4 + CD25 + FoxP3 + ;
B-regs, CD19 + CD41 hi CD38 hi ) are also often reduced or functionally defective, resulting in an uncontrolled expansion of autoreactive lymphocytes and plasma cells.
Notably, the spleen is a major player in this complex phenomenon, maintaining the derangement of immune homeostasis and representing the major site of autoantibody production. Consequently, circulating GPIIb/IIIa-reactive T and B cells are significantly decreased in patients achieving complete response after splenectomy (Kuwana et al, 2002) . Circulating memory B cells are also decreased in splenectomised patients (Martinez-Gamboa et al, 2009) . Indeed, interaction between GPIIb/IIIa autoantigens and reactive T and B lymphocytes inducing anti-platelet antibody production occurs primarily in the spleen, from where activated GPIIb/IIIa-reactive T and B lymphocytes are released into the circulation as memory cells. The spleen of ITP patients shows an increased number of autoreactive B-lymphocytes and a lower presence of T-regs in the red pulp (Olsson et al, 2012) and contains proliferative lymphoid nodules that accommodate proliferative B lymphocytes in close proximity to dendritic cells bound to IgM-GPIIb/IIIa autoantigen immune complexes (Daridon et al, 2012) . Although B-and T-regs are sequestered within spleen, explaining their reduced concentration in the peripheral blood of ITP patients, they are ineffective in controlling the exuberant autoreactive immunity. Moreover, the spleen is the repository of longlived plasma cells not affected by lymphocyte depletion through anti-CD20 antibodies (Mahevas et al, 2013) .
General criteria for treatment and course of disease
According to the International Working Group (IWG) criteria, ITP is classified into primary and secondary forms, where primary ITP is defined as an autoimmune disorder characterised by isolated thrombocytopenia (<100 9 10 9 /l) in the absence of any apparent cause or underlying disease (Rodeghiero et al, 2009 ). Splenectomy is not indicated in secondary forms, which may become apparent during a prolonged follow-up. The IWG-defined criteria of complete response (CR) and response (R) -previously called partial response (PR) -are based on post-treatment platelet count and distinguish 3 phases of the disorder: "newly diagnosed ITP", from diagnosis to 3 months; "persistent ITP" between 3 and 12 months; and "chronic ITP" for patients with ITP lasting more than 12 months (Rodeghiero et al, 2009) . The chances of "spontaneous" remissions are still high during the persistent phase, making deferral of more aggressive treatments to the chronic phase a sensible approach. Treatment should have two main aims: reduce bleeding risk and modify the natural course of the disease by inducing long-term response and, possibly, cure. More recently, increasing emphasis is given to patients' values and preferences, such as individual perception of surgery risks, major impact on quality of life, fatigue, body image, desire to conduct a fully normal life practicing sports and other leisure activities. Psychological and emotional aspects may be of more concern in children (Cooper, 2014) . In the light of a more liberal and personalised approach, some authors propose not to restrict new treatments to refractory patients (splenectomised patients requiring active treatment for their bleeding risk) (Chaturvedi & McCrae, 2016; Cuker & Neunert, 2016 ). This approach is at odds with other authoritative opinions (Hicks et al, 2014) .
The various treatments preferentially affect one or more of the main pathogenic mechanisms of the disease. For example, whereas intravenous immunoglobulins (IVIg) block the uptake by the reticulo-endothelial system of the opsonised platelets, increasing the platelet count for no longer than 3-4 weeks, corticosteroids, with their multifaceted effects on adaptive immunity and inflammatory milieu, may induce medium or long-term immunomodulation with sustained increased of platelet counts in some patients (Godeau et al, 2002; Provan et al, 2010) . This effect is further potentiated by the concomitant administration of rituximab, but with limited efficacy beyond 6-12 months, with the reconstitution of circulating B lymphocytes. Sustained normalization of the platelet count itself, independently from treatment, could favour immune tolerance. Whether the administration, early in the disease course, of an intensive intervention that simultaneously targets the innate and adaptive immune responses, increases cure rate or merely delays relapse at the expense of potentially greater toxicity remains unsettled (Cuker et al, 2015) . The removal of spleen is still the more effective intervention targeting multiple pathophysiological mechanisms of ITP and the only one able to substantially modify the course of the autoimmune process.
It is a consolidated view that ITP takes a different course and prognosis in children and adults. However, a comparative prospective observational study of children and adults by the Intercontinental Cooperative ITP Study Group (ICIS) shows that the distinction is more blurred than previously thought (unpublished observations). Sailer et al (2006) described a high remission rate in patients failing splenectomy treated conservatively. In historical series, only 20-30% of children are described to progress to chronicity while the remaining cases resolve spontaneously within a few months or 1-2 years with a watch-and-wait approach or with conservative on-demand treatments (corticosteroids and/or IVIg) (Kuhne et al, 2001) . With a prolonged follow-up at 5 years, more than 50% of chronic ITP will resolve with an attendant approach or with on-demand treatment (corticosteroids or IVIg), avoiding splenectomy. However, bleeding episodes may require hospitalization in about half of these patients (Rosthoj et al, 2012) .
Bleeding risk is also different in adults and children (Kuhne et al, 2001) . In a recent meta-analysis, Neunert et al (2015) estimated an incidence of intracranial haemorrhage of 0Á5% in children and 1Á5% in adults, more frequently in chronic phase. Other severe bleeds were more frequent in children (20Á2%) than in adults (9Á6%) (Neunert et al, 2015) . A French study reported visceral bleeding in around 5% of adults within 12 months from diagnosis (GrimaldiBensouda et al, 2016) . In some adult series the death rate of bleeding was similar to that of toxicity (Portielje et al, 2001) . Characteristics predictive of increased bleeding risk are still ill-defined. Very low platelet counts (<10-20 9 10 9 /l in children and <20-30 9 10 9 /l in adults), previous haemorrhages and older age are associated with an increased risk. Recent investigations suggest that the platelet function test could be a useful tool to predict bleeding severity in ITP independent of platelet count (Frelinger et al, 2015) , but adopting laboratory haemostasis evaluation in treatment decisions is premature and should not detract from accurate assessment of bleeding manifestation .
Consolidated results of splenectomy

Efficacy
In their systematic review, Kojouri et al (2004) analysed the response rate after splenectomy in 2623 patients from 47 adults-only series and 2463 from 38 series with up to 25% of children. At 29 months, CR (platelet count >100 9 10 9 /l) was maintained in 66% and CR plus PR (platelet count >30 9 10 9 /l) in 88%. After a minimum follow-up of 5 years (range 5-12Á75 years) CR was 64%. These figures were slightly higher in series including children (72% at 29 months and 71% at 5 years). The frequency of complete responses was not different across the 58 years of patient accrual. (Kojouri et al, 2004) .
Of 402 patients (24 aged <16 years) who underwent splenectomy between 1959 and 2002 in 22 Italian centres, 85Á6% responded to splenectomy, 23% of those initially responsive relapsed and 14% were refractory. Most relapsed or refractory patients responded to on-demand medical treatments, showing that splenectomy is safe and effective in approximately two-thirds of patients with chronic ITP. No differences were observed in adults vs children aged <16 years (Vianelli et al, 2005) . These results are in keeping with the general experience that after splenectomy the disease takes a milder course in most patients. These good results have been confirmed in more recent publications from both developed and developing countries. For example, in another European multicentre study, Vianelli et al (2013) analysed the data of 233 patients affected by ITP with a minimum follow-up of 10 years from surgery; 88% of patients were responsive. In 40% of cases (92/233) splenectomy was not satisfactory because of relapse or lack of response. The 20-year actuarial relapse-free survival was 67% for all responding patients (73% for CR and 27% for R) showing a great potential of cure. Notably, only 11% of the initial cohort needed a continuative treatment to maintain response (Vianelli et al, 2013) . In a report of 174 patients who underwent splenectomy from 1994 to 2014 in a single large hospital in China, a total of 88Á5% reached CR (72Á4%) or R (16Á1%). The overall response rate at long-term follow-up was 70%, and relapse-free survival at 20 years for patients with initial CR was estimated around 80% (Guan et al, 2017) . In a retrospective analysis of 167 patients with persistent or chronic ITP who were splenectomised between 1995 and 2009 in a single Indian hospital, the initial CR plus R rate was 86Á6% and 70% maintained response after a median follow-up of 54Á3 months (Ahmed et al, 2016) . A few recent studies have focused on the impact of age on the response rate of splenectomy. Gonzalez-Porras et al (2013) found a slightly lower rate of CR and R and higher relapse rate in patients older than 65 years, whereas no substantial difference was found in another study (Park et al, 2016) .
Many retrospective and prospective studies also confirmed a similar or higher efficacy of splenectomy in children with chronic ITP. For example, data from 153 children with a median follow-up of 2 years showed immediate platelet response in 86% with 80% maintaining their response in the following 4 years (Kuhne et al, 2007; Kuhne, 2017) .
Prediction of response
In their extensive review, Kojouri et al (2004) found that younger age (<50 years) was associated with better results. Previous response to glucocorticoids was also correlated with better response but was not confirmed in multivariate analysis. No substantial correlation was found with the previous response to IVIg. Also in more recent series, less favourable results, in terms of response rate and response duration, were generally (but not invariably) found in older patients (>65 years) and in those with no response to corticosteroids or with >2 prior lines of therapy, but these factors were not sustained upon multivariable analysis (Gonzalez-Porras et al, Park et al, 2016; Guan et al, 2017) . In the lack of reliable demographic and clinical predictors, determination of the principal site of platelet sequestration could be a very valuable tool. This approach was not consistently predictive in the analysis reported by Kojouri et al (2004) , where different radioisotope platelet labelling techniques ( 51 Cr or 111 In autologous or homologous platelets) were used (Kojouri et al, 2004) . A more updated pooled analysis of six studies in which Indium-labelled autologous platelet scanning (ILAPS) was used also resulted in inconclusive results (Sarpatwari et al, 2010) . Although patients with a splenic or predominantly splenic pattern of platelet sequestration by ILAPS showed a higher response rate following splenectomy than those with a hepatic, diffuse, or mixed pattern of sequestration (91% vs. 41%) the validity of this analysis was limited by differences among the studies with respect to the study population, definition of response, timing of assessment for response (with few data on long term response), and technical methodology and interpretation. Although promising (Sarpatwari et al, 2010) , the routine use of this technique as a tool to predict response to splenectomy in chronic ITP cannot be presently recommended outside centres with extensive experience with this modality (Cuker & Cines, 2010) . The validity of this technique has not been corroborated by additional studies with sufficient power and unbiased methodology (Roca et al, 2011 ) (Navez et al, 2015) .
Perioperative complications
Only short-term surgery-related complications were analysed by Kojouri et al (2004) . The mortality rate was 1% (48 out of 4955 patients) for laparotomy vs. 0Á2% (3/1301) for laparoscopy splenectomy. Similarly, more complications were observed with laparotomy splenectomy: 12Á9% (318/2465) vs. 9Á6% (88/921). Most complications were due to intraabdominal bleeding in patients with very low platelet count pre-surgery. After the first report of laparoscopic splenectomy for ITP (Delaitre & Maignien, 1991) , this technique has been increasingly adopted worldwide. A systematic review confirmed similar or even higher efficacy in terms of short-and long-term response with an estimated failure rate of 28% after 5 years of follow-up (Mikhael et al, 2009 ). Laparoscopic splenectomy is currently the gold standard in ITP, considering its better outcome in terms of perioperative complications (generally less than 10%) and low conversion rate to open surgery (<10% of cases), a better cosmetic outcome and the similar detection rate of accessory spleen. Furthermore, laparoscopic splenectomy requires a much shorter hospital stay, although at the expense of a slightly longer operation time, and involves less blood loss and quicker resumption of oral intake (Dolan et al, 2008; Rijcken et al, 2014) . Patients aged >60-70 years have a significantly increased risk of perioperative complications (Gonzalez-Porras et al, 2013; Park et al, 2016) . Wound, pulmonary or subphrenic infections, short febrile illness or subphrenic pleural effusions may be benign complications. Occasional perioperative deaths, still reported after laparoscopic splenectomy in recent series, could be virtually aborted by experienced surgeons with an appropriate surgical risk assessment, accurate preparation of patients assuring a safe preoperative platelet count and anti-thrombotic prophylaxis (Rodeghiero & Ruggeri, 2012) . Although laparoscopic splenectomy seems safe and feasible also in patients with platelets <10 9 10 9 /l with meticulous surgical technique (Cai et al, 2014) , other studies have suggested an increased risk of bleeding with platelets <20 9 10 9 /l (Keidar et al, 2005) . In patients responsive to a short-course of IVIg or other medical therapy, we suggest to increase platelet count before surgery to above 30-50 9 10 9 /l. We do not routinely use platelet transfusion. The risk of deep vein thrombosis (DVT) in the immediate post-surgery period is not different from that of minor surgery, whereas the risk of venous thrombosis in the splenic and venous portal (SVP) system might be significant, even more in laparoscopic surgery, due to the need to induce pneumoperitoneum with consequent venous stasis, so that standard prophylaxis with low molecular weight heparin (LMWH) is advised. Symptomatic SVP occurs at a relatively low frequency (1Á7%) (Krauth et al, 2008) , but it is also detected with much higher frequency (up to 20%) when systematic ultrasonography is performed in asymptomatic patients. LMWH prophylaxis should be administered for at least 10 days after surgery and stopped only after exclusion of SPV thrombosis by ultrasonography. During LMWH exposure, the platelet count should be maintained >30 9 10 9 /l (Rodeghiero & Ruggeri, 2012; Rodeghiero, 2016) . Major consequences have been reported when thrombi spread beyond splenoportal conjunction to different sites of the SVP system and patients require prolonged anticoagulation and clinical surveillance. Mesenteric vein thrombosis has also been rarely reported after splenectomy, also in ITP.
Infections
Overwhelming post-splenectomy infection (OPSI) is the more feared complication of splenectomy, with a mortality rate in in both children and adults of around 40-50% or higher and is mainly due to Streptococcus pneumoniae, Meningococcus meningitidis and Haemophilus influenzae type b. Infections by other pathogens that are not life-threatening may also occur at an increased rate. An extensive review on post-splenectomy infections in 6942 patients for the years 1966-1996, with a median follow-up of 6Á9 years, included 194 children and 283 adults with ITP. Sepsis was reported in 2Á6% and 2Á1% of children and adults respectively; corresponding deaths were 1Á5% and 1Á1% (Bisharat et al, 2001) . These rates are 2-3 times lower than those in patients splenectomised for sickle cell disease or thalassemia. So, it is fundamental to consider the risk of OPSI with precise reference to the underlying disorder. A Danish populationbased investigation compared the incidence of infections requiring hospitalization in patients splenectomised for various disorders from 1996 to 2005, without restricting the analysis to the most severe cases. Three reference groups were identified: general population, appendectomised and non-splenectomised patients with the same underlying disorder (matched indication comparison cohort) (Thomsen et al, 2009) . After 2Á2 years of follow-up, the overall rate of infections in patients splenectomised for any indication was 7Á7 vs. 2Á0/100 person-years in the general population, only slightly higher when compared for their indication-matched population, and 2-3 times higher when compared to appendectomised-matched patients. In 9976 non-splenectomised ITP patients, 1762 of whom had a second hospitalization for splenectomy, a long-term increased adjusted risk ratio for infection (1Á6-3Á1) was found in splenectomised versus not splenectomised after a median follow-up of 5 years (Boyle et al, 2013) . Given that sepsis has been reported up to 20-40 years after splenectomy, these investigations may have underestimated the actual long-term risk of infections, but, notably, most severe infections occur during the first 3 years (Kyaw et al, 2006) . Using the same Danish cohort reported by Thomsen et al (2009) and a similar methodology, Yong et al (2010) found a lower short-and long-term mortality risk with splenectomy in comparison with the matched indication cohort. In addition, the mortality risk ratio was lower than that of the matched indication cohort in the 3-12 months (0Á5) and >12 months (0Á4) periods, possibly indicating that non-splenectomised patients were more exposed to immunosuppression, leading to an increased death rate.
A much higher incidence of OPSI in the very young is a recurrent statement in the literature since the first report by King and Shumacker (1952) but poor evidence is offered to sustain an age-related risk. For example, the 1996 and 2002 reports of the British Committee for Standards in Haematology, without providing direct reference to original data, estimated an infection rate of >10% in infants <5 years splenectomised for trauma, much higher than in adults (<1%), with children with sickle cell anemia at especially high risk of OPSI (Working Party of the British Committee for Standards in Haematology Clinical Haematology Task Force, 1996; Davies et al, 2002) . Notwithstanding the limited direct evidence, we cautionary suggest to consider young children at particular high risk due to the immaturity of the immune system before the age of 5 and to the incomplete development of innate and adaptive immunity before 12 years (Holt, 1995; Georgountzou & Papadopoulos, 2017) .
Thrombosis
A slightly higher risk of venous thromboembolism (VTE) (max twice the control population) has been consistently found in ITP patients in large epidemiological studies, whereas the risk of arterial thrombosis (AT), also mildly increased, did not reach statistical significance. In these studies, splenectomy for ITP did not emerge as a significant additional risk factor (Rodeghiero, 2016 . In contrast, at least two large studies comparing splenectomised vs nonsplenectomised patients showed a higher risk of VTE and AT in patients who underwent splenectomy. Boyle et al (2013) found a 2Á7-fold higher long-term risk for VTE compared with matched non-splenectomised patients. In the first 3 months from surgery or index date, abdominal vein thrombosis was present in 1Á7% of splenectomised compared to 1% in control population (Boyle et al, 2013) . A multicentre retrospective study in 986 patients actively treated for ITP (for a total of 3,888 patient-years, median follow-up of almost 4 years), including 136 splenectomised patients, confirmed an increased thrombotic risk in splenectomised compared to non-splenectomised patients, with a hazard ratio of 4Á1 for VTE and of 3Á2 for AT (Ruggeri et al, 2014) . Older age, steroid use, splenectomy and a combination of at least three general vascular risk factors were also independent contributing risk factors for VTE and AT, although to a lesser extent than splenectomy.
Other long-term morbidities
Additional long-term morbidities possibly related to vascular events have been reported, but besides not being directly transferable to ITP, most studies suffer from major methodological weaknesses. An increased risk ratio of death due to ischaemic heart disease (1Á9 vs. control population) was reported in ex-servicemen that underwent splenectomy more than 15 years before for trauma during World War II, but the control population was not appropriately matched (Robinette & Fraumeni, 1977) . A single report, similarly based on very weak evidence, suggested an increased risk of vascular dementia in ITP, particularly in splenectomised (Ahn et al, 2002) . A few cases of pulmonary hypertension have been causally linked to splenectomy performed many years before (not for ITP) (Jais et al, 2005) . A recent Danish populationbased cohort study failed to find any significant increase of pulmonary arterial hypertension (and of myocardial infarction) in 379 splenectomised ITP patients when compared with their disease-matched cohort (Rorholt et al, 2017) . No evidence of increased risk of haematological or non-haematological cancer has been described in series separately analysing patients splenectomised for ITP (Rodeghiero & Ruggeri, 2012) . At variance with the quite homogeneous data from large series discussed so far, inconsistently higher or lower risks of infection or thrombosis were reported in small selected series, more prone to inclusion or methodological biases (Rodeghiero & Ruggeri, 2012) . However, in general, an increased mortality rate was not detectable when comparison was made with un-splenectomised controls (Boyle et al, 2013; Thai et al, 2016) . Updates on rituximab and TPO-RA
Rituximab efficacy and safety
Pioneered by Roberto Stasi in 2001 (Stasi et al, 2001) , the use of rituximab in chronic ITP has been the subject of hundreds of articles. Its use is still off-label and the initial enthusiasm has been progressively tempered. On average, 57% of both adults and children may initially respond, reaching a platelet count above 50 9 10 9 /l and only 38% of adults and 33% of children are still in response after 1 year. However, the response at 5 years further decreases to 21% in adults and 26% in children, without evidence that a plateau has been reached (Patel et al, 2012) . Similar results have been reported in a systemic review on 323 children with an overall response in 68% (complete response in 39%) and a median response duration of 12Á8 months (Liang et al, 2012) . Slightly better short-term results were observed in some series by adding one or more cycles of high dose dexamethasone (Zaja et al, 2010) . A double-blind, placebo-controlled randomised trial found no significant differences in long term response rate in patients previously treated with corticosteroids . A recent meta-analysis of randomised trials in adults confirmed that rituximab can slightly improve CR (but not R) at 6 months, but didn't offer substantial evidence for sustained responses beyond 6-12 months. No bleeding reduction was evident (Chugh et al, 2015) . Recently, a higher long-term response rate (up to 70%) has been obtained in young women treated within 2 years from diagnosis (Bussel et al, 2014; Marangon et al, 2017) .
As to its safety in ITP, in a systematic review, Arnold et al (2007) reported a death rate of 2Á9% among 306 evaluable patients, which was higher than that reported in most subsequent series, possibly indicating that more severe patients were treated initially. No increased risk of infection was found in the meta-analysis reported by Chugh et al (2015) . However, non-life threatening infections, severe infusion reactions and several other sporadic adverse effects have been reported, usually in less than 2-3% of cases. These may include reactivation of hepatitis B; late onset of usually short-lived neutropenia; transient or persistent reduced level of immunoglobulin. This latter adverse effect may be more frequent and severe in children and some authors have recommended immunoglobulin replacement therapy after rituximab administration, especially in children aged <5 years . A nationwide French registry report on 248 evaluable ITP adults treated with rituximab, with data collected during a median 2-year follow-up, confirmed that toxicity of this treatment is not negligible (Khellaf et al, 2014) . Three severe infusion reactions and reversible serum sickness, 11 cases of infections in 7 patients (3%) for a rate of 2Á3 infections/100 patient-years with 3 fatalities were reported. Other late events requiring hospitalization included transient neutropenia, transient heart failure and demyelinating neuropathy (Khellaf et al, 2014) . No deaths were reported in the systematic review on 208 children with ITP exposed to rituximab, but 16 patients experienced toxicities of grade 3 or 4, including infectious disease like pneumonia or varicella, development of common variable immunodeficiency (CVID), changes on the white matter of brain by magnetic resonance imaging, enteroviral meningoencephalitis and hypersensitivity reactions (Liang et al, 2012) . Other limitations related to rituximab are represented by impaired vaccine response for at least 6-12 months (Nazi et al, 2013) . In addition, rituximab crosses the placenta and women should to be counselled to avoid pregnancy during treatment and for up to 12 months after last rituximab exposure to exclude possible fetal damage (Chakravarty et al, 2011) .
TPO-RA efficacy and safety
Romiplostim and eltrombopag were approved by the USA Food and Drug Administration (FDA) in 2008 for patients with chronic ITP failing first-line therapy, splenectomised or not, and by the European Medicines Agency (EMA) in 2009, with restriction to splenectomised patients. In 2010, the EMA extended the indication also to non-splenectomised patients. Despite the discrepancy between the ICR and ASH guidelines in their preferential use with regard to splenectomy (George et al, 2014) , TPO-RA are now increasingly used and represent the major advancement in ITP treatment since 1981, when Paul Imbach introduced IVIg (Imbach et al, 1981; Rodeghiero & Ruggeri, 2015) . These agents are also finding a place for treating children (Lambert & Gernsheimer, 2017; Rodeghiero & Carli, 2017) . Based on registration and extension studies, up to 80% of patients respond and maintain a safe platelet count for an average of 60-70% of the exposure time, despite ample oscillations of platelet count in some patients. However, a slightly inferior response rate has been observed in clinical practice, with only 65% responsive at 2 years (Khellaf et al, 2011) . Whereas patients aged >65 years tend to obtain a better response in terms of platelet count, they appear to be burdened by a higher risk of severe adverse events, fatal adverse events and thromboembolic events compared to younger patients . Up to 10-30% of cases may experience a durable response off-treatment for 6 months or more (Gonzalez-Lopez et al, 2015; Newland et al, 2016; Cantoni et al, 2017) . Furthermore, subjects not responsive or intolerant to one agent may switch to the second with substantial benefit (Cantoni et al, 2017) .
The risk of increased reticulin deposition appears minimal and reversible with both romiplostim and eltrombopag, generally affecting less than 5-10%, including up to 2% with collagen deposition. Hepatobiliary laboratory alterations (in up to 15% of patients), mostly mild and reversible, and cataracts (in 9%) have been reported with eltrombopag (Janssens et al, 2016; Wong et al, 2017) .
There is indirect evidence of a much higher risk of both arterial and venous thrombosis in patients exposed to TPO-RA. Thrombosis was reported in 5-9% of cases, with an annualised rate of 3-5Á5/100 patients (up to 3-4 times that reported in the large studies of non-exposed ITP patients of similar age discussed before) (Rodeghiero, 2016 . However, matched control populations receiving placebo or standard of care are very limited in numbers and follow-up duration, so that any direct comparison is potentially biased. Thrombosis mainly occurred in patients with general risk factors and fatal events were also reported. However, some patients with thrombosis had their treatment continued to maintain a platelet count sufficient to safely administer antithrombotic treatment (Rodeghiero, 2016 . Interestingly, a pooled analysis across 13 completed clinical trials in adults with romiplostim showed that the thrombotic risk did not seem to be higher in splenectomised vs non-splenectomised ITP patients (Cines et al, 2017) .
Notably, in a prospective multicentre observational study 42% (142 out of 340 evaluable patients) discontinued romiplostim for various reasons before the end of the 2-year observation period . Less exciting results in terms of efficacy and safety were also reported in a monocentric cohort (Depre et al, 2016) . Furthermore, there are no convincing data that fatigue is abrogated with TPO-RA and data on the improvement of quality of life are weak and inconsistent.
Eltrombopag has been approved by the FDA and EMA (August 2015 and April 2016, respectively) for chronic ITP †In most series, up to 50% of patients are not appropriately vaccinated. Education of patients, vaccination policy and thrombosis prophylaxis are described in detail in Rodeghiero and Ruggeri (2012) . ‡Indium-labelled autologous platelet scanning might be useful if performed in centres with extensive experience. §The best treatment in patients with chronic (secondary) immune thrombocytopenia and common variable immunodeficiency has not been established, apart from replacement treatment with intravenous immunoglobulin, which may also increase platelet count. Splenectomy (risk of infection), rituximab (risk of infection and limited long-term response rate) and thrombopoietin receptor agonists (data from 2 to 3 anecdotal reports only and potential -although unlikely -risk of promoting haematological myeloid malignancies) all pose particular problems. Authors are divided as to preferring rituximab (Gobert et al, 2011) or splenectomy (Wong et al, 2013) . ¶ASA (American Society of Anesthesiologist) physical status classification (https://www.asahq.org/resources/clinical-information/asa-physical-sta tus-classification-system): I, healthy patient; II, mild systemic disease but no functional limitations; III, severe systemic disease with definite functional limitations; IV, severe systemic disease that is a constant threat to life; V, moribund patient unlikely to survive 24 h with or without operation. **Patients might develop splenectomy-related co-morbidities: continuing instructions on infections prevention, appropriate vaccination recalls and prophylaxis for thrombosis in at risk situations are advisable. showed improved platelet counts (62% and 75% responded at least once and 36% and 41% obtained a sustained response compared with minimal or null response in the placebo group) (Ehrlich et al, 2017) . Overall, these results were around 15-20% lower than in adults. Bleeding events were reduced (but not significantly for severe bleeds) and less concomitant ITP treatments were needed. No new toxicity signals were revealed and, in particular, no thrombosis or bone marrow fibrosis were found, but liver abnormality was confirmed as a relatively rare complication (3Á7% of exposed) Grainger et al, 2015) . Similar results were obtained with romiplostim in a phase 1/2 and a phase 3 study and in two openlabel ongoing studies reported in abstract form Grainger et al, 2016) . In these studies, 20-30% of children discontinued treatment and a single case of left arm DVT (out of 145 exposed) was described (Grainger et al, 2016) . These results need confirmation with a longer follow-up but already provide strong argument for considering the use of these agents in children with chronic ITP failing initial treatment and at risk of bleeding also outside clinical trials. Experience in clinical practice may differ from results of registration trials. For example, a multicentre retrospective study of paediatric ITP patients followed at ITP Consortium of North America (ICON) sites, retrospectively evaluated 79 children who had a total of 87 treatments (28 eltrombopag, 43 romiplostim, 8 both). The study confirmed the good initial response with a relatively low rate of stable responses (40%). However, 26% did not respond or lost their initial response and 2 patients had pulmonary embolisms while on treatment (1 with eltrombopag, 1 with romiplostim) . 
How current evidence can support a wise choice
Traditionally, the treatment of primary ITP has been based on corticosteroids and IVIg. More substantial immunosuppressive agents, such as mycophenolate mofetil, azathioprine and many others, with anecdotal evidence only , were reserved for unresponsive patients who refused or had contraindication(s) to splenectomy. Minimal doses of corticosteroids are still liberally used, in the mistaken belief that they are quite safe, whereas even doses of around 4-5 mg/day (just above the equipotent physiological daily incretion of glucocorticoids by adrenocortical cortex) have a cumulative toxicity, with increased risk of infection and metabolic complications. Rituximab and TPO-RA have been recently proposed as splenectomy-sparing or postponing alternatives. Reluctance to splenectomy is understandable from patients' perspective. Many will be unwilling to undergo an irreversible surgical approach, the long-term positive outcome of which (although probably outperforming the other options) cannot be reliably predicted. However, considering splenectomy as the last resort is not based on clear evidence. An adjusted comparison of mortality and morbidity in a French nationwide study showed better results of splenectomy vs rituximab (Moulis et al, 2014b) and splenectomy followed by rituximab was superior than rituximab before splenectomy at the three Mayo Clinic hospitals in USA (Hammond et al, 2016) . It's possible that non-splenectomised patients will ultimately receive a higher cumulative exposure to corticosteroids or other toxic treatments lifelong. Indeed, we lack direct comparative studies on long-term global outcomes of the different strategies derived from matched or, at least, comparable patients' cohorts exposed to splenectomy, rituximab and TPO-RA in variable sequences.
Closing remarks
To avoid fragmented analyses, properly designed prospective trials comparing long-term results of splenectomy vs alternative treatments in chronic ITP patients at risk of bleeding are needed, but the feasibility of such trials seems unlikely.
The comparisons and remarks in Table I suffer this limitation and the suggestions of Table II , although derived from the critical appraisal of the available evidence, are prone to subjective judgment.
Nevertheless, the current very low rate of splenectomies in most Western countries does not seem entirely justified. There is a general consensus that splenectomy should be postponed to the chronic phase and -understandably -most patients newly-diagnosed or in persistent phase prefer to try TPO-RA (licensed for chronic patients only), or possibly rituximab (off-label), after failure of initial treatments with corticosteroids/IVIg. However, splenectomy and its timing should be re-evaluated later on, if a durable response is not obtained, if other concomitant treatments like low dose corticosteroids are required or if the patient prefers not to stay indefinitely on treatment and monitoring,
The treating physician should construct a therapeutic alliance with the patient, proposing and prioritizing the various treatments according to their efficacy and safety in a shared decision-making model that takes into account patient's perspectives, beliefs, expectations and goals for his/her health and life, even more when the different proposed options are not based on strong evidence.
